Metabolic phenotyping for monitoring ovarian cancer patients

Epithelial ovarian cancer (EOC) is the most deadly of the gynecological cancers. New approaches and better tools for monitoring treatment efficacy and disease progression of EOC are required. In this study, metabolomics using rapid resolution liquid chromatography mass spectrometry was applied to a systematic investigation of metabolic changes in response to advanced EOC, surgery and recurrence. The results revealed considerable metabolic differences between groups. Moreover, 37, 30, and 26 metabolites were identified as potential biomarkers for primary, surgical and recurrent EOC, respectively. Primary EOC was characterized by abnormal lipid metabolism and energy disorders. Oxidative stress and surgical efficacy were clear in the post-operative EOC patients. Recurrent EOC patients showed increased amino acid and lipid metabolism compared with primary EOC patients. After cytoreductive surgery, eight metabolites (e.g. l-kynurenine, retinol, hydroxyphenyllactic acid, 2-octenoic acid) corrected towards levels of the control group, and four (e.g. hydroxyphenyllactic acid, 2-octenoic acid) went back again to primary EOC levels after disease relapse. In conclusion, this study delineated metabolic changes in response to advanced EOC, surgery and recurrence, and identified biomarkers that could facilitate both understanding and monitoring of EOC development and progression.

[1]  M. L. Genova,et al.  Mobility and function of coenzyme Q (ubiquinone) in the mitochondrial respiratory chain. , 2009, Biochimica et biophysica acta.

[2]  J. Lindon,et al.  Systems biology: Metabonomics , 2008, Nature.

[3]  T. Enomoto,et al.  Therapeutic strategies in epithelial ovarian cancer , 2012, Journal of Experimental & Clinical Cancer Research.

[4]  Claudio R. Santos,et al.  Lipid metabolism in cancer , 2012, The FEBS journal.

[5]  A. Davies,et al.  Untargeted UPLC-MS Profiling Pipeline to Expand Tissue Metabolome Coverage: Application to Cardiovascular Disease , 2015, Analytical chemistry.

[6]  In Koo Hwang,et al.  Indole‐3‐propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus , 2009, Journal of neuroscience research.

[7]  Tao Zhang,et al.  Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[8]  C. Gieger,et al.  Human serum metabolic profiles are age dependent , 2012, Aging cell.

[9]  S. Neumann,et al.  CAMERA: an integrated strategy for compound spectra extraction and annotation of liquid chromatography/mass spectrometry data sets. , 2012, Analytical chemistry.

[10]  L. Poisson,et al.  A metabolomic approach to identifying platinum resistance in ovarian cancer , 2014, Journal of Ovarian Research.

[11]  T. Krivak,et al.  Ovarian cancer screening and early detection in the general population. , 2011, Reviews in obstetrics & gynecology.

[12]  Age K. Smilde,et al.  UvA-DARE ( Digital Academic Repository ) Assessment of PLSDA cross validation , 2008 .

[13]  Ming-zhu Yin,et al.  Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform , 2012, Acta oncologica.

[14]  Kang Li,et al.  Plasma Metabolic Profiles in Women are Menopause Dependent , 2015, PloS one.

[15]  O. Saugstad.  Hypoxanthine as an Indicator of Hypoxia: Its Role in Health and Disease through Free Radical Production , 1988, Pediatric Research.

[16]  M. Terris,et al.  Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[17]  D. Galaris,et al.  Uric acid and oxidative stress. , 2005, Current pharmaceutical design.

[18]  Tianlu Chen,et al.  Urinary metabonomic study on colorectal cancer. , 2010, Journal of proteome research.

[19]  J. Dungan,et al.  Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer , 2011 .

[20]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[21]  M. Schäfer,et al.  Perioperative Nutrition in Abdominal Surgery: Recommendations and Reality , 2011, Gastroenterology research and practice.

[22]  Xiaohua Wu,et al.  Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. , 2011, Journal of proteome research.

[23]  Tao Zhang,et al.  Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. , 2013, Journal of proteome research.

[24]  Kp Suresh.  An overview of randomization techniques: An unbiased assessment of outcome in clinical research , 2011, Journal of human reproductive sciences.

[25]  T. Lehtimäki,et al.  A metabolic view on menopause and ageing , 2014, Nature Communications.

[26]  G. Lou,et al.  Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling. , 2015, Molecular bioSystems.

[27]  Masahide Takahashi,et al.  Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  G. Lou,et al.  Large‐scale profiling of metabolic dysregulation in ovarian cancer , 2014, International journal of cancer.

[29]  P. Borst,et al.  Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? , 2012, Open Biology.

[30]  T. Athersuch.  Metabonomics , 2018, Unraveling the Exposome.

[31]  R. Kuang,et al.  Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment , 2013, Front. Oncol..

[32]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[33]  W. Wick,et al.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.

[34]  Chaofu Ke,et al.  Identification of biomarkers for unstable angina by plasma metabolomic profiling. , 2013, Molecular bioSystems.

[35]  F. Moussallieh,et al.  Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy , 2011, Journal of oncology.

[36]  M. A. Khan,et al.  Association of lipid metabolism with ovarian cancer. , 2010, Current oncology.

[37]  Sham S. Kakar,et al.  Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer , 2011, PloS one.

[38]  R. Abagyan,et al.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. , 2006, Analytical chemistry.

[39]  Daniel K Nomura,et al.  Global profiling strategies for mapping dysregulated metabolic pathways in cancer. , 2012, Cell metabolism.

[40]  Johan Trygg,et al.  Chemometrics in metabonomics. , 2007, Journal of proteome research.